Hinge Health price target raised to $65 from $61 at Canaccord

Canaccord raised the firm’s price target on Hinge Health (HNGE) to $65 from $61 and keeps a Buy rating on the shares. The firm said they posted another stellar quarter where the outlook appears favorable both in the near-term with a guidance raise that more than factors in the 3Q beat and longer-term with discussion of the potential of the new HingeSelect offering and foreshadowing of a service line expansion that may be sooner than previously anticipated.